Dr Stephen Strickland speaks to ecancer at the ASH 2019 meeting in Orlando about the VITAL trial of vosaroxin and infusional cytarabine for the frontline treatment of acute myeloid leukaemia (AML).

He explains that the trial focused on a high-risk patient population, including patients who were over 6555years of age or who were 18-54 with high-risk features.

Dr Strickland reports that the combination was reasonably safe and well-tolerated in this patient population. He suggests that it has the potential to replace anthracyclin based induction in the first setting.